High-value-added products for healthcare settings and revenue management
First written in FY2016. 24 of 34 entries say "Advanced", first in FY2018-Q1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「SurFlo Midela, Japan’s first indwelling-needle midline catheter, was launched at healthcare institutions in Japan.」
For high-value-added products for healthcare settings, a midline catheter was launched with the aims of minimally invasive use, safety and reducing the burden on both patients and healthcare professionals. - FY2026-H1AdvancedAnnual report
「In Japan, although revenue from the Hospital Care Solutions business declined following the termination of certain businesses and other factors, the Pharmaceutical Solutions business grew, resulting in a 1.0% year-on-year increase in revenue. Overseas sales increased 2.0% year on year, led by North America and Europe. As a result, global revenue increased 1.3% year on year to ¥105.6 billion.」
At the Medical Care Solutions Company, the impact of terminating certain businesses remained, while growth in the Pharmaceutical Solutions business and higher sales in North America and Europe drove a 1.3% increase in global revenue. - FY2025AdvancedAnnual report
「Sales began of Rachetta, a portable medical body composition analyzer.」
For high-value-added products for healthcare settings, a new product was launched to measure perioperative nutritional status, muscle mass and body water, supporting individualized nutritional intervention and treatment. - FY2025-H1AdvancedAnnual report
「In Japan, expanding demand for the Hospital Care Solutions and Pharmaceutical Solutions businesses, together with pricing measures, resulted in a 7.5% year-on-year increase in revenue. Overseas revenue increased 20.8% year on year, led by the Americas. As a result, global revenue increased 11.0% year on year to ¥104.3 billion.」
At the Medical Care Solutions Company, expanding demand for Hospital Care and Pharmaceutical Solutions, together with pricing measures, contributed to an 11.0% year-on-year increase in global revenue. - FY2024-Q3AdvancedAnnual report
「In Japan, lower revenue from nutritional foods in the Hospital Care Solutions business transferred in the previous fiscal year was partially offset by higher revenue from infusion-related products and the Pharmaceutical Solutions business, resulting in a 0.7% year-on-year decline in revenue. Overseas revenue increased 7.1% year on year due to foreign exchange effects. As a result, global revenue increased 1.2% year on year to ¥147.3 billion.」
Infusion-related products and the Pharmaceutical Solutions business partially offset the decline in Japan following the sale of the nutritional foods business, and the Medical Care Solutions Company’s global revenue increased 1.2% year on year. - FY2024-Q2AdvancedAnnual report
「In Japan, sales of nutritional foods in the Hospital Care Solutions business transferred in the previous fiscal year and thermometers in the Life Care Solutions business declined, resulting in a 2.0% year-on-year decrease in revenue. Overseas sales increased 6.9% year on year, primarily due to foreign exchange effects. As a result, global revenue increased 0.2% year on year to ¥94.0 billion.」
The Medical Care Solutions Company’s revenue declined in Japan due to lower sales of nutritional foods and thermometers, but increased 0.2% year on year globally on higher overseas revenue, turning to slight growth from a 5.0% decline in FY2024-Q1. - FY2024-Q1Decline in revenue from the Medical Care Solutions businessAnnual report
「As a result, global revenue declined 5.0% year on year to ¥43.7 billion.」
The Medical Care Solutions Company’s global revenue declined 5.0% year on year, due to lower sales of nutritional foods transferred in the previous fiscal year and changes in delivery timing in the Pharmaceutical Solutions business. - FY2023AdvancedAnnual report
「Because Ziextenzo® 3.6 mg subcutaneous injection is administered automatically, using it on the same day as cancer chemotherapy eliminates the need for a hospital visit the following day for administration. This is expected to reduce the burden of hospital visits on patients and the workload of healthcare professionals.」
For high-value-added products for healthcare settings, an automatically administered combination product was launched, providing tangible value by reducing the burden on both patients and healthcare professionals. - FY2023-Q3AdvancedAnnual report
「In Japan, despite the delayed recovery in healthcare demand, the Pharmaceutical Solutions business and adhesion-prevention materials in the Hospital Care Solutions business performed well, resulting in a 2.3% year-on-year increase in revenue. Overseas sales were strong, increasing 13.8% year on year. As a result, global revenue increased 4.9% year on year to ¥145.5 billion.」
Pharmaceutical Solutions, adhesion-prevention materials and the overseas business contributed to a 4.9% year-on-year increase in global revenue for the Medical Care Solutions Company. - FY2023-Q2AdvancedAnnual report
「In Japan, pharmaceuticals and adhesion-prevention materials in the Hospital Care Solutions business, as well as the Pharmaceutical Solutions business, grew, but sales declined slightly due to the delayed recovery in healthcare demand. Overseas sales remained strong, increasing 13.9% year on year. As a result, global revenue increased 2.0% year on year to ¥93.8 billion.」
Pharmaceuticals, adhesion-prevention materials and Pharmaceutical Solutions contributed to a 2.0% year-on-year increase in global revenue for the Medical Care Solutions Company. - FY2022AdvancedAnnual report
「In the Hospital Care Solutions business, the new model Telfusion Infusion Pump 18 was launched in Japan. The product retains the ease of use of previous models, while improving visibility and portability and adding near-field communication functionality. It is positioned as an entry-level model suitable for use in all healthcare settings, with overseas expansion planned from fiscal 2022 onward and a long-term global sales target of approximately 10,000 units.」
In high-value-added products and services, a new infusion pump with communication functionality was launched, with overseas expansion from fiscal 2022 onward and a sales target of approximately 10,000 units. - FY2022-Q3AdvancedAnnual report
「In the Hospital Systems Business, sales of infusion pumps and syringe pumps remained strong in both Japan and overseas as healthcare demand recovered and healthcare systems were further strengthened. Alliance business also continued to expand. Global revenue was ¥138.7 billion, up 7.5% year on year.」
Infusion pumps, syringe pumps and the alliance business contributed to a 7.5% year-on-year increase in the Hospital Company’s global revenue. - FY2022-Q2AdvancedAnnual report
「In Japan, alliance business with pharmaceutical companies expanded, and infusion and syringe pumps in the Hospital Systems business performed well. Overseas, demand for high-turnover products showed a marked recovery in North America's veterinary market and in Asia, and global revenue increased 12.4% year on year to ¥92.0 billion.」
Alliance business, infusion and syringe pumps, and overseas demand for high-turnover products contributed to a 12.4% year-on-year increase in global revenue at the Hospital Company. - FY2022-Q1AdvancedAnnual report
「In Japan, demand recovered for high-turnover products in the Hospital Systems business, while alliance business with pharmaceutical companies also expanded. Overseas, demand for high-turnover products showed a marked recovery in North America's veterinary market and in Asia and China, and global revenue increased 11.7% year on year to ¥43.8 billion.」
Global revenue at the Hospital Company increased 11.7% year on year, driven by recovering demand for high-turnover products and the expansion of alliance business with pharmaceutical companies. - FY2021AdvancedAnnual report
「The Hospital Company's revenue increased 2.7% from the previous fiscal year to ¥175.5 billion.」
Expansion of infection-control products, anesthetic analgesics and alliance business with pharmaceutical companies demonstrated the results of high-value-added products and services for healthcare settings and revenue management through full-year revenue growth. - FY2021-Q3Recovery in Hospital Business revenueAnnual report
「Although many products in Japan were affected by the spread of COVID-19, sales of infection-control products and anesthetic analgesics in the Hospital Systems Business provided support. In addition, alliance business with pharmaceutical companies expanded globally. As a result, Hospital Company's revenue was ¥129.0 billion, up 1.0% year on year.」
Infection-control products, anesthetic analgesics and alliance business, which are considered high-value-added products, contributed to a 1.0% year-on-year increase in the Hospital Company's revenue. - FY2021-Q2Shift to lower revenue in the Hospital BusinessAnnual report
「In Japan, although many products were affected by the spread of COVID-19, the Hospital Company's revenue was ¥81.8 billion, down 1.2% year on year, as anesthetic analgesics and infection-control products in the Hospital Systems business provided support and the alliance business expanded its partnerships with pharmaceutical companies globally.」
Although anesthetic analgesics, infection-control products and alliance business with pharmaceutical companies provided support, the Hospital Company's revenue declined 1.2% year on year, changing from growth in FY2021-Q1 to a decline. - FY2021-Q1Continuity of operations amid changing demandAnnual report
「Although many products in Japan were affected by the spread of COVID-19, sales of anesthetic analgesics, thermometers, ultraviolet irradiation robots, and hand sanitizers in the Hospital Systems Business provided support. In addition, alliance business with pharmaceutical companies expanded overseas. As a result, Hospital Company's revenue was ¥39.2 billion, down 1.4% year on year.」
The decline in the Hospital Company's revenue was limited to 1.4% year on year due to increased demand for high-value-added products and the expansion of alliance business with pharmaceutical companies. - FY2020AdvancedAnnual report
「The company is expanding its lineup of infusion and syringe pumps used in ICUs and hospital wards that can connect with hospital IT systems, while promoting projects with medical institutions and IT-related companies to improve safety and security in healthcare settings and achieve more efficient healthcare through digitalization.」
The direction of high-value-added products and services was given concrete form through hospital IT connectivity, digitalization projects with medical institutions and IT companies, and expansion of contract development and manufacturing services for pharmaceutical companies using PLAJEX. Hospital Company revenue increased 3.1% from the previous fiscal year to ¥171.0 billion. - FY2020-Q3AdvancedAnnual report
「In addition to strong performance by the spray-type adhesion barrier AdSpray and the anesthetic analgesic fentanyl injection in the Hospital Systems Business, alliance business with pharmaceutical companies expanded. As a result, Hospital Company's revenue was ¥127.8 billion, up 1.5% year on year.」
AdSpray, fentanyl injection and alliance business with pharmaceutical companies contributed to a 1.5% year-on-year increase in the Hospital Company's revenue. - FY2020-Q2AdvancedAnnual report
「In addition to strong performance by infusion pumps and syringe pumps in the Hospital Systems Business, the spray-type adhesion barrier AdSpray and the antipyretic analgesic Acelio, alliance business with pharmaceutical companies expanded. As a result, Hospital Company's revenue was ¥82.8 billion, up 2.0% year on year.」
Infusion pumps, syringe pumps, AdSpray, Acelio and alliance business with pharmaceutical companies grew, resulting in a 2.0% year-on-year increase in the Hospital Company's revenue. - FY2020-Q1AdvancedAnnual report
「Sales were strong for the spray-type adhesion barrier AdSpray and the antipyretic analgesic Acelio in the Hospital Systems business, while the alliance business expanded its partnerships with pharmaceutical companies, resulting in a 2.4% year-on-year increase in the Hospital Company's revenue to ¥39.8 billion.」
AdSpray, Acelio and alliance business with pharmaceutical companies performed well and expanded, resulting in a 2.4% year-on-year increase in the Hospital Company's revenue. - FY2019AdvancedAnnual report
「Sales were strong for infusion solutions, the spray-type adhesion barrier AdSpray, infusion-line products such as closed-system infusion systems, and the antipyretic analgesic Acelio in the Hospital Systems business. In addition, the alliance business expanded its partnerships with pharmaceutical companies in Japan and overseas, resulting in a 4.4% increase in the Hospital Company's revenue to ¥165.8 billion from the previous fiscal year.」
The Hospital Company's full-year revenue increased 4.4% from the previous fiscal year, driven by growth in high-value-added products and alliance business with pharmaceutical companies. - FY2019-Q3AdvancedAnnual report
「Sales were strong for infusion solutions, the spray-type adhesion barrier AdSpray and the antipyretic analgesic Acelio in the Hospital Systems business. In addition, the alliance business expanded its partnerships with pharmaceutical companies, resulting in a 4.7% year-on-year increase in the Hospital Company's revenue to ¥125.9 billion.」
Infusion solutions, AdSpray, Acelio and alliance business with pharmaceutical companies grew, resulting in a 4.7% year-on-year increase in the Hospital Company's revenue. - FY2019-Q2AdvancedAnnual report
「Sales were strong in the pain-management field, including the Hospital Systems business's analgesic Acelio, as well as the spray-type adhesion barrier AdSpray. In addition, the alliance business expanded its partnerships with pharmaceutical companies, resulting in a 4.5% year-on-year increase in the Hospital Company's revenue to ¥81.2 billion.」
The pain-management business, AdSpray and alliance business with pharmaceutical companies grew, resulting in a 4.5% year-on-year increase in the Hospital Company's revenue. - FY2019-Q1AdvancedAnnual report
「In Japan, sales were strong in the pain-management field, including the Hospital Systems business's antipyretic analgesic acetaminophen intravenous solution Acelio Injection 1000mg, as well as the spray-type adhesion barrier AdSpray. In addition, the alliance business expanded its partnerships with pharmaceutical companies, resulting in a 5.3% year-on-year increase in the Hospital Company's revenue to ¥38.8 billion.」
The pain-management business, AdSpray and alliance business with pharmaceutical companies expanded, resulting in a 5.3% year-on-year increase in the Hospital Company's revenue. - FY2018-Q3AdvancedAnnual report
「Sales of the Terufusion Infusion Pump Type 28, launched in Japan in August, remained firm. Sales of products for pain management and peritoneal dialysis also increased, and the Hospital Company's revenue rose 1.1% year on year to ¥120.2 billion.」
The Terufusion Infusion Pump Type 28 was launched in August, and sales of products for pain management and peritoneal dialysis also increased. The Hospital Company's revenue increased 1.1% year on year. - FY2018-Q2RestatedAnnual report
「In addition to distributor inventory adjustments for medical equipment products and restrained purchases of infusion and syringe pumps in the first quarter, the Hospital Company's revenue was ¥77.7 billion, down 0.7% year on year, partly due to the impact of supply discontinuations and account rationalization for products in the pharmaceutical and healthcare fields to improve profitability.」
The company continues to describe supply discontinuations and account rationalization aimed at improving profitability. The Hospital Company reported lower revenue, partly due to distributor inventory adjustments and other factors. - FY2018-Q1AdvancedAnnual report
「In addition to discontinuing supplies and rationalizing accounts for products in the pharmaceutical and healthcare fields to improve profitability, the Hospital Company's revenue was ¥36.9 billion, down 3.9% year on year, partly because the alliance business expects more orders in the second half of the current fiscal year than in the second half of the previous fiscal year.」
This describes specific measures taken to improve earnings through high-value-added products and revenue management, including supply discontinuations and account rationalization. - FY2017ReframedAnnual report
「The Hospital Company provides proprietary technologies and services and contributes to improving the quality and efficiency of healthcare and innovating drug delivery, thereby shifting its focus toward revenue growth and aiming to transition to a stage of sustainable growth.」
The company explicitly stated that it would transition from explaining earnings improvement through high-value-added products and revenue management to a stage of sustainable growth centered on revenue growth. - FY2017-Q3RestatedAnnual report
「In Japan, sales of infusion-line products, including closed-system infusion systems, remained strong at the Hospital Company. In Asia, sales of indwelling needles also remained firm.」
This continues to describe high-value-added products such as closed-system infusion systems and the rollout of indwelling needles in Asia. - FY2017-Q2RestatedAnnual report
「In Japan, sales of infusion-line products, including closed-system infusion systems, remained firm at the Hospital Company.」
This continues to describe the rollout of products for healthcare settings, including closed-system infusion systems. - FY2017-Q1RestatedAnnual report
「In Japan, sales of closed-system infusion systems, infusion pumps and syringe pumps remained firm at the Hospital Company.」
This reiterates the sales performance of products for healthcare settings and the product rollout of closed-system infusion systems, infusion pumps and related products. - FY2016First statedAnnual report
「The Hospital Company aims to achieve further earnings improvement by providing high-value-added products tailored to the needs of healthcare settings and implementing rigorous revenue management.」
Examples cited include smart pumps, closed-system infusion systems, prefilled syringes, intradermal delivery devices and vital-sign measurement equipment with communications capabilities.